Key result
Pioglitazone reduces carotid intima-media thickness by ~0.08 mm versus control in type 2 diabetes.
Why the study?
There was uncertainty about whether PPARγ activators like pioglitazone have antiatherogenic or protoatherogenic effects in type 2 diabetes patients.
Absolute Event Rate: -0.084% vs 0.022%
p-value: p=<0.001
No takes yet. Share an insight, caveat, or question.
May slow carotid IMT progression in type 2 diabetes; leaves open net vascular effects of PPARγ agonists.
Hiroyuki Koshiyama (2001) studied Type 2 diabetes (n=106). Pioglitazone vs. Control group was evaluated on Change in carotid arterial intima-media thickness (IMT) (p=<0.001). Pioglitazone significantly decreased carotid arterial intima-media thickness compared to control after 6 months (-0.084 mm vs 0.022 mm, P<0.001) in Japanese subjects with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: